

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

- Claims 1-107. **[Cancelled]** A modified antibody that binds an antigen, said modified antibody comprising a variant human IgG1 Fc region, wherein said variant human IgG1 Fc
- Claim 108. **[Previously Presented]** A mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959.
- Claim 109. **[Previously Presented]** An antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959, or antigen-binding fragment thereof.
- Claim 110. **[Previously Presented]** The antibody of claim 109 which is a F(ab')₂ fragment.
- Claim 111. **[Previously Presented]** The antibody of claim 109 which is a F(ab') fragment.

- Claim 112. **[Withdrawn]** The antibody of claim 109 which is conjugated to a therapeutic agent.
- Claim 113. **[Withdrawn]** The antibody of claim 112, wherein the therapeutic agent is a cytotoxin.
- Claim 114. **[Currently Amended – Withdrawn]** The antibody of claim 113 wherein said cytotoxin is paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, ~~mitomycin~~ mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, a glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, or cyclophosphamide.
- Claim 115. **[Withdrawn]** The antibody of claim 109 comprising at least one modification in the Fc region.
- Claims 116-122. **[Cancelled]**
- Claim 123. **[Currently Amended]** A pharmaceutical composition comprising (i) a therapeutically effective amount of an antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959, or an antigen-binding fragment thereof; and (ii) a pharmaceutically acceptable carrier.
- Claim 124. **[Cancelled]**

- Claim 125. **[Withdrawn]** A method of treating or preventing an IgE-mediated allergic disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no PTA-5962, clone 2D11 having ATCC accession no. PTA- 2960, and clone 1F2 having ATCC accession no. PTA-5959, or an antigen binding fragment thereof.
- Claim 126. **[Currently Amended -- Withdrawn]** The method of claim 125, wherein said IgE-mediated allergic disorder is asthma, allergic rhinitis, a gastro-intestinal ~~allergies~~ allergy, eosinophilia, conjunctivitis, or glomerular nephritis.
- Claim 127. **[Withdrawn]** The method of claim 125, wherein said patient is human.
- Claim 128. **[Withdrawn]** The method of claim 125, wherein said antibody is humanized.
- Claim 129. **[Withdrawn]** The method of claim 125, wherein the antibody is a F(ab')₂ fragment.
- Claim 130. **[Withdrawn]** The method of claim 125, wherein the antibody is a F(ab') fragment.
- Claim 131. **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a chimeric version, or antigen-binding fragment thereof.

- Claim 132. **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a humanized version, or antigen-binding fragment thereof.
- Claim 133. **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a F(ab')₂ fragment.
- Claim 134. **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a F(ab') fragment.
- Claim 135. **[Previously Presented]** The antibody of claim 109, wherein said antibody is a chimeric version, or antigen-binding fragment thereof.
- Claim 136. **[Previously Presented]** The antibody of claim 109, wherein said antibody is a humanized version, or antigen-binding fragment thereof.